‘Putting Electric Motors Into Classic Cars’ – Burt Sets Out European Potential Of Value Added Medicines

Medicines For Europe’s New Sector Chief Highlights Opportunities For Innovation

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Pharmanovia CEO James Burt recently took over as chair of Medicines for Europe’s value added medicines sector group. In an exclusive interview with Generics Bulletin, he looks to the future for innovation around known medicines in Europe, including landmark EU legislation on the horizon and the importance of stakeholder dialogue throughout the supply chain.

James Burt at Medicines For Europe's VAM conference, November 2023
James Burt addresses Medicines for Europe’s fifth annual value added medicines conference • Source: Medicines for Europe

Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in November, not only marked a milestone for the sector in Europe – in the form of EU legislative efforts to recognise the value of repurposed medicines with a proposed four-year period of data exclusivity protection for new indications (Also see "European Opportunities Loom For Value Added Medicines" - Generics Bulletin, 15 November, 2023.) – but also marked the transition from one Medicines for Europe value added medicines sector chair to the next.

At the conference, James Burt – formerly head of the EMENA region at Accord Healthcare, now CEO of value added...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

Neuraxpharm Enters Japanese Market 1

 
• By David Wallace

Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

Hyloris Sets Out Plans To Expand Its Pipeline

 
• By Akriti Seth

After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

Awards Offers Two Weeks Of Online Networking

 
• By David Wallace

From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

Hyloris And Purna Strike Value-Added Development Deal

 
• By David Wallace

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.